أخبار السوق اليوم — عناوين الأسهم والعملات الرقمية المنتقاة بالذكاء الاصطناعي

The US FDA has announced a crackdown on copycat weight-loss drugs, specifically targeting Hims & Hers, a telehealth company that has undercut Novo Nordisk's obesity shot prices, raising concerns about regulatory compliance and market competition.

The Dow Jones Industrial Average surpassed the 50,000 mark, driven by a rally in chip stocks, particularly Nvidia, AMD, and Broadcom, due to increased spending on AI data centers by Amazon and Alphabet.

Eli Lilly's weight loss pill is on track for a second-quarter launch in the US, pending FDA approval, with the company expressing optimism about the progress.

The FDA rejected AstraZeneca's subcutaneous version of its lupus medicine, potentially impacting the company's revenue and market share in the lupus treatment market.

ImmunityBio's stock soars after the FDA outlines a resubmission path for ANKTIVA in bladder cancer, indicating a positive development for the company's plans.

ImmunityBio's stock is experiencing a sharp rally after the FDA outlined a resubmission path for its ANKTIVA treatment in bladder cancer, boosting investor sentiment.

Akeso's CFO expresses confidence in the company's cancer drug ivonescimab receiving FDA approval, citing a positive outlook for the regulatory process.

Regeneron's Chief Scientific Officer George Yancopoulos discussed the company's hearing loss gene therapy and weight loss drugs at the JP Morgan healthcare conference, highlighting the FDA's response and future plans.

FDA Commissioner Dr.

The FDA has cleared Novo Nordisk's Wegovy pill for launch next month, a potential game-changer in the weight-loss market.

The US stock market, bonds, and dollar are experiencing volatility ahead of the highly anticipated US jobs report, indicating a cautious investor sentiment.

FDA Commissioner Dr.